Better Science, Better Lives: Women's Health Research at Yale is Working for You
Across the country, it’s becoming clearer every day: We must study the health of women. We must study the influence of sex-and-gender differences on health. And it’s time for all aspects of medical research and practice to embrace this change.
What Black Women With Ovarian Cancer Need to Know About Genetic Testing
If you are a Black American who’s already living with ovarian cancer, genetic testing may not be top of mind. But medical guidelines state that anyone diagnosed with ovarian, fallopian tube, or primary peritoneal cancer should be offered genetic testing, because it can help you make informed decisions about your cancer journey. Having genetic testing after an ovarian cancer diagnosis could actually mean saving your life, as well as the lives of both the women and men in your family. But, because Black Americans with ovarian cancer are far less likely than white Americans to get genetic testing, it’s important to have all the information and resources available to make sure everyone who needs testing has access to it. “If you don’t know your underlying genetic test results, you can’t be offered life-preserving or lifesaving therapy,” says Elena Ratner, MD, a gynecologic oncologist at Yale Cancer Center in New Haven, Connecticut.Source: Everyday Health
Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Yale Physicians Share the Symptoms of Ovarian Cancer
September is ovarian cancer awareness month and while ovarian cancer is rare, the survival rate is low. Ovarian cancer is not easily detectable in its early stages. According to the American Cancer Society, the most common symptoms include bloating, pelvic-abdominal pain, and urinary symptoms. News 8 spoke with co-directors of the Sexual Intimacy and Menopause Program at Smilow Cancer Hospital in New Haven.Source: WTNH
Why the Latest Screening Tests and Treatments Offer Hope for Ovarian Cancer
Ovarian cancer is the second most common gynecologic cancer in the United States. It also accounts for more deaths than any other cancer of the female reproductive system, according to the Centers for Disease Control and Prevention (CDC).Source: Everyday Health
Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer
Thanks in part to research begun more than a decade ago with funding from Women’s Health Research at Yale, Dr. W. Mark Saltzman is working with colleagues on a way to deploy effective cancer-fighting medication safely with the help of nanoparticles.
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Carocari Gift to Support Dr. Schwartz’s Ovarian Cancer Research
Deborah Carocari was only 36 when she was diagnosed with a rare form of advanced but low-grade ovarian cancer. At that time she received a prognosis of several months to a year from her physician, Peter Schwartz, MD, now the John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences and Vice Chair, Gynecology. Debbie went on to defy those odds and battle the cancer for the next two decades. Although she ultimately succumbed to the disease, a generous gift from her estate is now making possible further ovarian cancer research by Dr. Schwartz.
HEALTH NOTES: Black and Hispanic Cancer Patients Are Underrepresented in Clinical Trials
A new study has shown that clinical trials for new cancer medications rarely analyze data on safety and effectiveness by race and that black and Hispanic patients are consistently underrepresented among participants.